PREOPERATIVE ADMINISTRATION OF RECOMBINANT HUMAN ERYTHROPOIETIN TO THE PATIENTS UNDERGOING OPEN HEART SURGERY

Abstract

Recombinant human erythropoietin (rHuEPO) was administered to sixteen patients who was to undergo open heart surgery for the purpose of reducing the amount of homogenous blood transfusion. The rHuEPO was administered intravenously three times a week for three weeks before the operation. Eight patients received 6000 IU at a time (6000 unit group) and another eight patients received 9000 IU (9000 unit group). All patients were given ferrous sulphate (210mg iron) orally every day for three weeks before the operation. The autologous blood was reserved weekly 400ml at a time, if hemoglobin was more than 11.0g/dl. The amount of autologous blood reservation was 1058±279ml in the 6000 unit group and 1000±566ml in the 9000 unit group. There were no significant differences in the volume of reserved autologous blood between the two groups. There were also no significant differences between them in the counts of red blood cell, hemoglobin and hematocrit at the starting point. Although, these values in the 9000 unit group at the time of operation were (444±48)×104/mm3, 12.9±0.9g/dl and 41.5±2.9%, versus (378±23)×104/mm3, 11.2±1.0g/dl and 36.1±3.1% respectively in the 6000 unit group. All these values in the 9000 unit group were significantly higher than those in the 6000 unit group (p=0.02•0.02•0.02). Operation without homogenous blood transfusion was accomplished four out of eight patients in the 6000 unit group, while seven out of eight in the other. It is concluded that the administration of the 9000 unit of rHuEPO is superior to that of the 6000 unit for autologous blood donation before open heart surgery.

Ähnliche Arbeiten